November 28, 2024

CRC 1249 – Funding for Collaborative Research Centre in Chemistry

CRC 1249 – Funding for Collaborative Research Centre in Chemistry

The German Research Foundation providing funding of around 10,9 million euros

With a Collaborative Research Centre in chemistry, Heidelberg University has been successful in the latest approval round of the German Research Foundation (DFG). The CRC 1249 “N-Heteropolycycles as Functional Materials”, where research is being carried out on novel organic compounds, is entering its third funding period. The DFG is providing funding of around 10,9 million euros for the research consortium over a period of four years. Prof. Dr Petra Tegeder from the Institute for Physical Chemistry at Ruperto Carola will serve as spokesperson.

Petra Tegeder
Petra Tegeder | © private

The focus of CRC 1249 is the development of novel organic functional materials with specifically tunable electronic and optical properties and their application as photoactive components and organic semiconductors. This is done on the basis of a large and flexibly variable class of organic hydrocarbon compounds with ring structures containing nitrogen atoms. The research plan comprises the development of synthetic-chemical methods, structural and spectroscopic characterization as well as the theoretical modeling of molecules, aggregates and solid films. Of particular interest is the way in which molecular properties are related to the optoelectronic properties of materials and devices.

The Collaborative Research Centre is supported by researchers from the three Institutes of Chemistry, the Interdisciplinary Center for Scientific Computing and the Institute for Molecular Systems Engineering and Advanced Materials at Heidelberg University. Research groups from the Karlsruhe Institute of Technology and the Max Planck Institute for Solid State Research in Stuttgart are also participating. The CRC 1249 will reach the maximum funding period of twelve years.

Further information

Participating Institutions

Our latest News

discover more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp